{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-101874","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2024-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.165717+00:00","generated_at":"2026-05-31T02:27:34.585446+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Black Diamond reports initial Phase 2 data for BDTX-1535 showing 42% ORR in recurrent EGFRm NSCLC","bullets":["200 mg daily dose selected for pivotal development; favorable tolerability with no new safety signals.","Preliminary ORR of 42% (8/19) in patients with C797S or PACC osimertinib-resistance mutations; 14/19 remain on therapy.","Duration of response ~8+ months for first 3 partial responders; mean follow-up 4.7 months.","Regulatory feedback on registration path expected Q1 2025; initial first-line data expected Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-101874","json":"https://secwatch.observer/filing/0001104659-24-101874.json","markdown":"https://secwatch.observer/filing/0001104659-24-101874.md","text":"https://secwatch.observer/filing/0001104659-24-101874.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000110465924101874/0001104659-24-101874-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000110465924101874/tm2424526d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T02:27:34.585446+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}